<DOC>
	<DOC>NCT00502385</DOC>
	<brief_summary>The study will be conducted across multiple European centres to assess the safety and tolerability of multiple doses of AZD2171 in patients with AML.</brief_summary>
	<brief_title>Phase I AZD2171 in Patients With Relapsed or Refractory AML and Elderly Patients With DeNovo or Secondary AML</brief_title>
	<detailed_description />
	<mesh_term>Cediranib</mesh_term>
	<criteria>Provision of written informed consent Male/female, 18 yrs or over WHO performance status 02 Disease not responding to or relapsing after chemotherapy or elderly patients not suited to chemotherapy Acute myeloid leukaemia arising from previous chronic myeloid leukaemia or acute myeloid leukaemia of type FAB M3 Previous treatment against new blood vessel formation (antiangiogenic) Chest Xray showing leukaemia in the lungs</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2011</verification_date>
	<keyword>Phase I</keyword>
	<keyword>AML</keyword>
	<keyword>de novo or secondary AML</keyword>
	<keyword>AZD2171</keyword>
</DOC>